Skip to main content
CALIWAY BIOPHARMACEUTICALS CO., LTD. logo

CALIWAY BIOPHARMACEUTICALS CO., LTD. - Investor Relations & Filings

Listed IPO Oct 2024
Ticker · 6919 ISIN · TW0006919004 LEI · 984500D2D587B98A7B13 TW Professional, scientific and technical activities
Open in API
Filings indexed 86 across all filing types
Latest filing 2026-04-21 AGM Information
Country TW Taiwan
Listing TW 6919

About CALIWAY BIOPHARMACEUTICALS CO., LTD.

www.caliwaybiopharma.com

Caliway Biopharmaceuticals Co., Ltd. is a clinical-stage company specializing in the discovery and development of small-molecule therapeutics for medical aesthetics and chronic inflammatory diseases. The company focuses on high-value markets with significant unmet medical needs, utilizing unique pharmacological mechanisms to create niche products. Its lead candidate, CBL-514, is a first-in-class injectable drug designed to induce adipocyte apoptosis for non-surgical local fat reduction, cellulite, and the treatment of Dercum’s disease. Other pipeline assets include CBA-539, a long-acting injectable for pigmentation and anti-aging, and CBF-520, which targets central obesity and visceral fat reduction. Caliway aims to redefine aesthetic medicine and inflammatory disease management through innovative, non-invasive treatments that offer improved safety and efficacy over existing therapies.

Recent filings

Filing Released Lang Actions
115年年報及股東會資料 — 2026_6919_20260522F13.pdf
AGM Information Classification · 95% confidence The document is titled as a shareholder meeting manual for the 115th Annual General Meeting (AGM) of 康霈生技股份有限公司. It includes detailed agenda items such as meeting procedures, reports, approvals, discussions, elections, and other proposals. The document contains attachments including the business report, audit committee review report, auditor's report with financial statements, directors' remuneration report, and other governance-related appendices. The content is comprehensive and includes financial data, audit opinions, and management reports, which are typical components of an Annual Report or AGM Information. However, the document is specifically structured as a meeting manual for the AGM, containing the agenda and materials to be discussed and approved at the meeting, rather than the standalone annual report itself. Therefore, it fits best under AGM Information (AGM-R) as it is the presentation and materials shared during the Annual General Meeting, not the full annual report filing itself.
2026-04-21 Chinese
115年年報及股東會資料 — 2026_6919_20260522F02.pdf
AGM Information Classification · 100% confidence The document is titled as the "115 年股東常會 議事手冊" which translates to the "115th Annual General Meeting (AGM) Handbook" for 康霈生技股份有限公司. It includes detailed agenda items typical of an AGM such as meeting procedures, reports, approvals, discussions, elections, and other motions. The document contains attachments including the business report, audit committee review report, directors' remuneration report, financial statements, and other governance-related materials. The presence of detailed agenda, reports, and election items confirms this is the official meeting materials for the Annual General Meeting. It is not merely an announcement or a summary but the full meeting handbook with substantive content for the AGM. Therefore, the document fits the category AGM Information (AGM-R).
2026-04-21 Chinese
115年年報及股東會資料 — 2026_6919_20260522FE2.pdf
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a comprehensive “2026 Annual Shareholders’ Meeting Handbook” containing the meeting agenda, reporting items, approval and discussion proposals, election matters, and extensive appendices (business report, audit committee report, financial statements, articles of incorporation, etc.). It serves as the information package sent to shareholders to explain matters to be voted on at the Annual General Meeting. This matches the definition of a Proxy Solicitation & Information Statement.
2026-04-21 English
115年年報及股東會資料 — 2026_6919_20260522F01.pdf
AGM Information Classification · 100% confidence The document is a detailed notice for the 115th Annual General Meeting (AGM) of 康霈生技股份有限公司, including information about the meeting date, location, agenda items such as reports, approvals, discussions, elections, and other shareholder meeting procedures. It contains proxy forms, voting instructions, and candidate lists for board elections. The content is focused on the AGM logistics and materials for shareholders to participate and vote. There is no financial data or report content itself, but rather the meeting notice and related materials. Therefore, this document fits the category of AGM Information (AGM-R). The document length and detail confirm it is not a brief announcement or a report publication notice but the actual AGM materials.
2026-04-21 Chinese
本公司新藥CBL-514注射劑用於減少腹部皮下脂肪之第二個 多國多中心樞紐三期臨床試驗CBL-0302申請，今日已完成美國 FDA送件
Regulatory Filings Classification · 85% confidence The document is a corporate regulatory disclosure made via the Taiwan Stock Exchange’s “公開資訊觀測站” system. It details a material event (the FDA IND submission for a new drug’s Phase III trial) and does not present financial results, board changes, dividends, or other specific filing types. It is not a standalone financial report, earnings release, management presentation, or prospectus; thus it falls into the general regulatory announcements fallback category.
2026-04-20 Chinese
114年第4季財務報告書 — 202504_6919_AIC.pdf
Audit Report / Information Classification · 93% confidence The document contains the full independent auditor’s report and detailed parent-company only financial statements (balance sheets, statements of income, cash flows, notes, etc.) for the years ended December 31, 2025 and 2024. It is a standalone audited financial statement package rather than a full annual management report or simple announcement. Therefore, it fits the definition of Audit Report / Information (AR). FY 2025
2026-04-17 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.